Skip to main content
Journals

The Invisible Scar: Energy-Based Facial Tightening Through the Lens of the Deep-Layer Facelift Surgeon

Aesthetic Surgery Journal
Aesthetic Surgery Journal

Authors: Tara M Chadab, MD, MS , Aaron L Wiegmann, MD, MS , Rod J Rohrich, MD
Abstract: Energy-based devices are widely used for facial rejuvenation; as a result, an increasing proportion of patients presenting for facelift or necklift surgery have a history of prior treatment with ultrasound- or radiofrequency-based technologies. While the efficacy and safety of these devices are well established, their cumulative effects on facial soft tissues critical to deep-layer facelift surgery remain under-recognized. This article examines three commonly used energy-based facial tightening modalities—microfocused ultrasound, high-frequency parallel beam ultrasound, and fractional radiofrequency microneedling—from the perspective of the facelift surgeon. Device-specific mechanisms of action and tissue-level effects are reviewed, followed by discussion of their potential operative implications and the senior author's experience-informed strategies for managing these patients. Recognition of these effects is essential for patient counseling, operative planning, and preservation of long-lasting surgical outcomes.

JOURNAL ARTICLE

Related Articles

Melasma is a chronic, relapsing hyperpigmentation disorder that is difficult to treat, particularly in Fitzpatrick skin types III-V, where energy-based devices frequently induce postinflammatory hyperpigmentation (PIH). Radiofrequency microneedling (RFMN) has emerged as a promising alternative because it targets dermal pathology while minimizing epidermal injury.
Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.